In conversation with...
The Lancet Neurology
Our Editors and and the journal’s authors explore their research and its impact on people’s health, health care, and health policy in this regular podcast.
Episodes
Mark Hallett on functional neurological disorderMay 13, 2022
Eva Feldman on advances in understanding ALSApril 13, 2022
Estrella Morenas-Rodriguez and Christian Haass on soluble TREM2 and Alzheimer'sApril 06, 2022
John Collinge on a treatment for CJDMarch 16, 2022
Alexandra Durr on riluzole in patients with spinocerebellar ataxia type 2February 22, 2022
Giuseppe Citerio on frailty and TBIJanuary 19, 2022
Alberto Costa on memantine in adolescents and young adults with Down syndromeDecember 20, 2021
Olivier Rascol on amantadine for patients with movement disordersNovember 17, 2021
Antonio Uccelli on stems cells for MSOctober 20, 2021
Priya Palta on blood pressure control and cognitive declineSeptember 15, 2021
Adam Boxer on tau biomarkersAugust 18, 2021
Irene Cortese on the difficulties of designing clinical trialsJuly 21, 2021
Doug Turnbull on mitochondrial diseases in adultsJune 16, 2021
Geert Jan Biessels on predicting post-stroke cognitive impairmentMay 19, 2021
Henk-Jan Westeneng on the causal effects of pre-symptomatic lifestyle on ALSApril 21, 2021
Anne MacGregor on menstrual migraineMarch 17, 2021
Peter Rothwell on asymptomatic carotid stenosis and strokeFebruary 17, 2021
Spinal cord injury and degenerative cervical myelopathyJanuary 20, 2021
Genetic risk factors for sCJDDecember 22, 2020
Prednisone in short-term prevention of cluster headacheNovember 24, 2020
PET imaging of inflammation in neurological and psychiatric disordersOctober 21, 2020
Neurological associations of COVID-19September 05, 2020
Advances in understanding of Rett syndromeJuly 31, 2020
Management of Parkinson's diseaseJune 17, 2020
Optimal time to treat Huntington's DiseaseMay 26, 2020
Eva Feldman on advances in understanding ALSApril 13, 2022
Estrella Morenas-Rodriguez and Christian Haass on soluble TREM2 and Alzheimer'sApril 06, 2022
John Collinge on a treatment for CJDMarch 16, 2022
Alexandra Durr on riluzole in patients with spinocerebellar ataxia type 2February 22, 2022
Giuseppe Citerio on frailty and TBIJanuary 19, 2022
Alberto Costa on memantine in adolescents and young adults with Down syndromeDecember 20, 2021
Olivier Rascol on amantadine for patients with movement disordersNovember 17, 2021
Antonio Uccelli on stems cells for MSOctober 20, 2021
Priya Palta on blood pressure control and cognitive declineSeptember 15, 2021
Adam Boxer on tau biomarkersAugust 18, 2021
Irene Cortese on the difficulties of designing clinical trialsJuly 21, 2021
Doug Turnbull on mitochondrial diseases in adultsJune 16, 2021
Geert Jan Biessels on predicting post-stroke cognitive impairmentMay 19, 2021
Henk-Jan Westeneng on the causal effects of pre-symptomatic lifestyle on ALSApril 21, 2021
Anne MacGregor on menstrual migraineMarch 17, 2021
Peter Rothwell on asymptomatic carotid stenosis and strokeFebruary 17, 2021
Spinal cord injury and degenerative cervical myelopathyJanuary 20, 2021
Genetic risk factors for sCJDDecember 22, 2020
Prednisone in short-term prevention of cluster headacheNovember 24, 2020
PET imaging of inflammation in neurological and psychiatric disordersOctober 21, 2020
Neurological associations of COVID-19September 05, 2020
Advances in understanding of Rett syndromeJuly 31, 2020
Management of Parkinson's diseaseJune 17, 2020
Optimal time to treat Huntington's DiseaseMay 26, 2020